Formycon targets 20% biosimilar development efficiency gain with AI-enabled Phlexglobal eTMF platform

Bitget2026/10/06 04:30

Formycon rolled out an AI-enabled eTMF platform to centralize trial master files across current, future biosimilar clinical programs. Internal assessment targets roughly 20% efficiency gains from the new system, supporting its lean-development FYB4GROWTH strategy. AI tools were also introduced to analyze manufacturing process data, aiming to speed contractor work and support critical quality-attribute evaluation. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Formycon AG published the original content used to generate this news brief via EQS News (Ref. ID: corporate_2410760_de) on October 06, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.